Welcome to QBiotics
- We are an unlisted Australian public company.
- We discover, develop and commercialise novel anticancer and wound healing pharmaceuticals for human and veterinary markets.
- Our lead drug, tigilanol tiglate, is a small molecule anticancer pharmaceutical targeting a range of solid tumours across multiple species.
- The simultaneous development of products for both the vet and human markets enables validation of technology and reduces risks for human development, while generating early revenues.
